Cartesian Therapeutics, Inc. (RNAC) is a Healthcare stock trading at $10.04 (as of 2026-08-21), with a market capitalization of $294.84M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
Cartesian Therapeutics is a clinical-stage biopharmaceutical company developing nanoparticle immunomodulatory drugs, with its lead gene therapy SEL-302 in Phase I and biologic programs such as SEL-212 in Phase III, and it makes money mainly through license and collaboration revenue.
The profit model is driven by development-stage execution rather than ongoing product sales, so revenue is limited and results hinge on clinical trial progress across programs like SEL-302 (Phase I) and SEL-212 (Phase III).
| Collab & License | $0.0B |
Business quality (Weak): Clinical-stage focus with negative operating economics in the latest quarter, and performance visibility tied to specific trial programs and operating signals like license and collaboration revenue.
| Price | $10.04 |
| Market Cap | $294.84M |
| Price / Sales | 152.93 |
| FCF Yield | -51.5% |
| Revenue (TTM) | $2.80M |
| Net Margin | -4658.6% |
| Revenue Growth (YoY) | -92.8% |
| EPS Growth (YoY) | 12.1% |
| FCF Growth (YoY) | 142.3% |
| Altman Z-Score | -4.63 (distress) |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Top Institutional Holder | Squarepoint Ops LLC ($13.77M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Carsten Brunn |
| Employees | 66 |
| Country | US |
| IPO Date | 2016-06-22 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.